Home
Careers
Conferences
Directory
Genes
InDepth
Marketing
News
Reports
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
Pharmaceutical Market Trends, 2008 - 2012: key market forecasts & growth opportunities
2.
Top-10 Biotech Companies - Market Outlook, 2008-2023
3.
Competitor Analysis: Janus Kinase (JAK) Inhibitors
4.
Enzyme Replacement & Enhancement Therapies (ERT)
5.
The Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles)
6.
The Cancer Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
7.
Protein Therapeutics Markets
8.
European Clinical Trial Site Options: An Insiders Analysis Overview
9.
Quality for Biologics
10.
Mammography World Markets
Best Sellers:
1.
Contract Research Annual Review 2008
2.
The Pharmaceutical Wholesale and Distribution Industry Outlook and Analysis 2008
3.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
4.
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts The challenge of turning technology into therapy
5.
Orthopedics - Global Industry Guide
6.
Competitor Analysis: c-MET/HGF Inhibitors
7.
Competitor Analysis: Alzheimers Disease Antibodies
Market Opportunity in the G-Protein Coupled Receptors GPCRs Target Space
G-protein coupled receptors (GPCRs) have proven to be a highly amenable target class to successful therapeutic intervention via small-molecule drugs. There are 324 distinct molecular drug targets for all classes of approved pharmaceuticals of which 25 percent modulate GPCRs.
The therapeutic utility of GPCR agonists and antagonists across a broad disease space has lead to the development of a number of targeted drugs. The drugs are applied to the following diseases:
Asthma
Cardiovascular Disease
Central Nervous System (CNS) Disorders
Pain
Other therapeutic indications
D&MD's Market Opportunity in the G-Protein Coupled Receptors (GPCRs) Target Space: Qualitative and Quantitative Market Metrics is a focused market analysis report that provides the latest analysis of the GPCR target space in terms of druggable targets available, quantitative metrics defining the space, and therapeutic candidates in various clinical stages of the developmental pipeline.
Of the 324 distinct molecular targets for pharmaceuticals, GPCRs represent 25% of the total pharmaceutically-addressed drug targets today and therefore are the most-druggable target family. This D&MD report presents the current state of the GPCR marketplace both qualitatively and in quantitative terms.
Unique Benefits of This Report
Identify key technology drivers through a detailed analysis of the developmental and applicatory technological trends within the GPCRs space
An up-to-date presentation of the key qualitative and quantitative metrics describing the GPCR target space
Quantitative market opportunity for GPCR interrogation/analysis
The current pipeline of GPCR-targeting therapeutics being developed-all current candidates are presented together with their clinical status, drug targets addressed, companies developing these candidates, and likelihood of progression through the developmental pathway
Figures and charts are presented that describe the features/trends in the GPCRs space-useful for business planning, corporate, and investor presentations
Published: January, 2007
Pages: 240 Format PDF
Table of Contents
Price: $4,950.00 / GBP3,267.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.